Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

UK surgeons hail ‘world first’ op to tackle leading cause of sight loss

The gene therapy operation in which a virus is injected into the eye through syringe. (NIHR Oxford Biomedical Research Centre)
The gene therapy operation in which a virus is injected into the eye through syringe. (NIHR Oxford Biomedical Research Centre)

Surgeons have claimed a world first after carrying out a gene therapy operation to tackle the most common cause of sight loss in the UK.

Age-related macular degeneration (AMD) causes the deterioration of cells in the macular, the central part of the retina, and affects more than 600,000 people in the UK.

Medics at the John Radcliffe Hospital said their pioneering operation could have a real impact on the quality of life and independence of those who suffer from AMD.

The John Radcliffe Hospital
The John Radcliffe Hospital (Steve Parsons/PA)

Janet Osborne, 80, from Oxford, who underwent the procedure, has AMD in both eyes and, as is typical, her left eye has deteriorated more than the right.

She said her restricted vision makes simple tasks like preparing vegetables, sewing and recognising faces difficult.

She said: “I wasn’t thinking of me. I was thinking of other people. For me, I hope my sight doesn’t get any worse. That would be fantastic. It means I wouldn’t be such a nuisance to my family.”

Mrs Osborne’s operation is the first phase of the trial testing the safety of the procedure, said a spokesman for the National Institute for Health Research’s (NIHR) Oxford Biomedical Research Centre.

Her vision will be monitored regularly over the coming months to gauge the success of the operation.

The op involves detaching the retina and injecting a solution containing a virus underneath.

Janet Osborne, 80, from Oxford, underwent a gene therapy operation to tackle the loss of her eye sight due to the condition AMD. (NIHR Oxford Biomedical Research Centre)
Janet Osborne (NIHR Oxford Biomedical Research Centre/PA)

Robert MacLaren, professor of ophthalmology at the University of Oxford, who carried out the procedure, said: “AMD is the number one cause of untreatable blindness in the developed world.

“A genetic treatment administered early on to preserve the vision in patients who would otherwise lose their sight would be a tremendous breakthrough and certainly something I hope to see in the near future.

“We’re harnessing the power of the virus, a naturally occurring organism, to deliver the DNA into the patient’s cells.

“When the virus opens up inside the retinal cell it releases the DNA of the gene we have cloned, and the cell starts making a protein that we think can modify the disease, correcting the imbalance of the inflammation caused by the complement system.

“The idea of this gene therapy is to ‘deactivate’ the complement system, but at a very specific point at the back of the eye, so the patient would otherwise be unaffected by it, and we hope that in future it will slow down the progression of macular degeneration.”

The therapy is intended to preserve what vision patients have remaining and halt the effects of AMD.

It is hoped the procedure can be used early enough before the deterioration of eyesight begins.

The clinical trial was carried out by Prof MacLaren with the support of the Oxford Biomedical Research Centre.

It was sponsored by Gyroscope Therapeutics, a UK company that develops genetically defined therapies for the treatment of eye diseases.